There is no better way to create wealth than investing in stocks. Not gold, not bonds, not real estate.

Global health aid agency Unitaid has written to Johnson & Johnson's (J&J) CEO Joaquin Duato, urging him to take "immediate action" to expand access to the company's tuberculosis drug bedaquiline.

Johnson & Johnson said on Thursday its cancer therapy combination met the main goal in a late-stage study testing it as a treatment for patients with a type of lung cancer.

J&J recently spun off its slowest-growing business -- consumer health. The healthcare giant aims to focus its resources in its pharmaceuticals and medtech units, which together generated more than ...

The market had one of its worst weeks of the year, as the SPDR S&P 500 ETF Trust NYSE: SPY tumbled almost 3% lower. The selloff swept the market last week after the Federal Reserve signaled that in...

J&J's stock fell steeply following its share exchange offer for Kenvue stock, but dip buyers have since returned, auguring well for a further recovery. JNJ's best-in-class "A+" profitability grade ...

Protagonist Therapeutics, Inc.'s oral IL-23 drug for psoriasis, JNJ-2113, must show non-inferior efficacy to Johnson & Johnson's injectable Tremfya before further development. JNJ-2113 is the only ...

Kenvue faces significant challenges in the consumer healthcare sector, including sluggish growth, intense competition, and middle-tier brand positions. While the company has manageable debt levels,...

Johnson & Johnson reported solid second quarter results - with MedTech reporting double-digit growth - and raised its full-year guidance for fiscal 2023. Kenvue is now a stand-alone company, and in...

Johnson & Johnson's strategic transformation, marked by the split-off of its consumer health division, is a significant shift in its corporate strategy. The company aims to streamline its operation...

Johnson & Johnson had spun off Kenvue, its consumer health division, to boost growth in its more profitable pharmaceutical and medical technology sectors. JNJ achieved a steady 3.3% revenue growth ...

Johnson & Johnson is attractively valued and well-positioned for long-term growth, with a 3.0% dividend yield and a AAA-rated balance sheet. The company has faced challenges due to the baby powder ...

Johnson & Johnson announced that it's ditching the classic cursive script it has used for 130 years in favor of a revamped logo that pays homage to the old design.

Johnson & Johnson is replacing its instantly recognizable logo that's been in use for 135 years.

Johnson & Johnson said Thursday that it will replace the well-known signature script with a modern look that reflects its sharpened focus on pharmaceuticals and medical devices.